Premium
BRAF p.V600E‐specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling
Author(s) -
Galuppini Francesca,
Pennelli Gianmaria,
Loupakis Fotios,
Lanza Cristiano,
Vianello Luca,
Sacchi Diana,
Mescoli Claudia,
Salmaso Roberta,
Agostini Marco,
Lonardi Sara,
Farinati Fabio,
Rugge Massimo,
Fassan Matteo
Publication year - 2017
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.13315
Subject(s) - medicine , surgical pathology , colorectal cancer , university hospital , general surgery , oncology , pathology , cancer
The assessment of BRAF p.V600E mutational status has already become an essential part of the diagnostic routine in colorectal cancer (CRC). Indeed, on one side, the BRAF mutational status is regarded as being a key molecular marker to definitely decide the most proper therapeutic options in a selected cohort of patients. On the other, it is used to exclude a suspicious of Lynch Syndrome in case of MLH1 absence in deficient mismatch repair (dMMR) tumors [1]. This article is protected by copyright. All rights reserved